Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prof Wilhelm to step down from Wilex

This article was originally published in Scrip

Executive Summary

Wilex co-founder Professor Olaf G Wilhelm will step down as chief executive officer of the company and chair of the executive management board when his director's contract expires on 31 March 2014. Wilex said Professor Wilhelm would leave the firm "in view of the future direction of the company and the necessary adjustments by mutual consent with the supervisory board." Professor Wilhelm helped found the Munich, Germany-based company in 1997 and has served as CEO since 2001. He will be replaced by current chief financial officer Dr Jan Schmidt-Brand – effective 1 April 2014. The company said this decision reflected the re-positioning of Wilex, which is planning to focus on its ADC technology and push the commercialization of clinical development projects with a team of approximately 50 employees with emphasis in Ladenburg.

You may also be interested in...

A Backstage View Of Roche’s Recent Collaborations

In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.

Fact File: Coronavirus Medtech And Diagnostic Updates

As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts